2026· [Rinsho ketsueki] The Japanese journal of clinical hematology· Vol 67 7, pp.
819-827
· 0 citations
Medicine
TL;DR
Emerging strategies to ameliorate GVHD without attenuating GVL, including intensified local therapy, selective trafficking blockade, S1PR modulators that limit pathogenic T-cell migration, and tissue-protective agents that enhance epithelial regeneration and prevent the establishment of inflammatory memory are summarized.
Relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) affects 40–50% of recipients and remains the leading cause of posttransplant mortality; median overall survival is approximately 5 months and 1-year survival is below 20%. Conventional salvage—chemotherapy, immu...
Naif I. Aljohani, Ahlam Almasari, Zayed Alzahrani et al.· Frontiers in Immunology· 0 citations
Although studies on HLA-haploidentical hematopoietic stem cells transplant (HSCT) for high-risk acute myeloid leukemia (AML) showed that regulatory and conventional T-lymphocyte (Treg/Tcon) immunotherapy prevents graft-versus-host disease (GvHD) while it exerts T-cell dependent graft-versus-leukemia (GvL) effect, its m...
L. Ruggeri, Antonio Pierini, E. Urbani et al.· Blood Advances· 0 citations
A focused Perspective asks whether GvHD directed engineering has made clinically significant product-associated GvHD rare and whether allogeneic CAR-T must reduce donor-to-host alloreactivity while managing the distinct host-versus-graft barrier.
Nabeel Ahmed, Jawaria Jabeen· Transplantation and Cellular...· 0 citations
Acute Myeloid Leukemia (AML) is biologically heterogeneous, clinically aggressive and is characterized by the uncontrolled clonal expansion of immature myeloid progenitors in the bone marrow microenvironment. Despite the achievement of remission with frontline treatments, relapse is disturbingly common and is the major...
A. Mathew, Ronak Raheja, Pranav Thomas Alex· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.